for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ジョンソン・エンド・ジョンソン

JNJ.N

現在値

149.18USD

変化

2.01(+1.37%)

出来高

6,627,060

本日のレンジ

146.20

 - 

149.64

52週レンジ

109.17

 - 

157.00

∙ 約20分前の相場を表示しています。

適時開示

Johnson & Johnson Says XWPharma Completes $40 Mln Financing and Appoints Leonard Blum as CEO

Sept 17 (Reuters) - Johnson & Johnson <JNJ.N>::XWPHARMA - COMPLETED A $40 MILLION SERIES C FINANCING.XWPHARMA - FINANCING WAS LED BY PANACEA VENTURE, WITH PARTICIPATION FROM EXISTING INVESTORS, JOHNSON & JOHNSON INNOVATION.

Momenta Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period In Connection With Proposed Sale To Johnson & Johnson

Sept 15 (Reuters) - Momenta Pharmaceuticals Inc <MNTA.O>::MOMENTA PHARMACEUTICALS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD IN CONNECTION WITH PROPOSED SALE TO JOHNSON & JOHNSON.MOMENTA PHARMACEUTICALS INC - TRANSACTION IS EXPECTED TO CLOSE IN EARLY OCTOBER 2020.

SpringWorks Therapeutics Announces Clinical Collaboration With Janssen

Sept 14 (Reuters) - SpringWorks Therapeutics Inc <SWTX.O>::SPRINGWORKS THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH JANSSEN TO EVALUATE NIROGACESTAT IN COMBINATION WITH TECLISTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SPRINGWORKS THERAPEUTICS - JANSSEN WILL SPONSOR AND CONDUCT PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF COMBINATION.SPRINGWORKS THERAPEUTICS - JANSSEN WILL ASSUME ALL COSTS ASSOCIATED WITH STUDY, OTHER THAN EXPENSES RELATED TO MANUFACTURING OF NIROGACESTAT.SPRINGWORKS THERAPEUTICS - WILL ALSO FORM A JOINT OVERSIGHT COMMITTEE WITH JANSSEN.

Health Canada Approves Tremfya (Guselkumab Injection), A First-In-Class Selective Interleukin (Il)-23 Inhibitor For Active Psoriatic Arthritis

Sept 10 (Reuters) - Johnson & Johnson <JNJ.N>::HEALTH CANADA APPROVES TREMFYA (GUSELKUMAB INJECTION), A FIRST-IN-CLASS SELECTIVE INTERLEUKIN (IL)-23 INHIBITOR FOR ACTIVE PSORIATIC ARTHRITIS.

Janssen Submits Application Seeking U.S. FDA Approval Of Darzalex Faspro For The Treatment Of Light Chain Amyloidosis

Sept 10 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN SUBMITS APPLICATION SEEKING U.S. FDA APPROVAL OF DARZALEX FASPRO™ (DARATUMUMAB AND HYALURONIDASE-FIHJ) FOR THE TREATMENT OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS.JANSSEN PHARMACEUTICAL COMPANIES - SBLA IS BEING REVIEWED UNDER FDA REAL-TIME ONCOLOGY REVIEW (RTOR) PROGRAM.

Janssen To Discontinue Pimodivir Influenza Development Program

Sept 2 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN TO DISCONTINUE PIMODIVIR INFLUENZA DEVELOPMENT PROGRAM.JANSSEN PHARMACEUTICAL -DECISION BASED ON RECENT RESULTS FROM PRE-PLANNED INTERIM ANALYSES OF PIMODIVIR PHASE 3 TRIAL IN HOSPITALIZED PATIENTS WITH INFLUENZA A.JANSSEN - DATA SHOW THAT PIMODIVIR DOES NOT OFFER A BENEFIT ABOVE EXISTING STANDARD OF CARE.JANSSEN - PIMODIVIR PHASE 3 TRIAL IN INFLUENZA A FOUND PIMODIVIR IN COMBINATION WITH SOC WAS VERY UNLIKELY TO DEMONSTRATE ADDED BENEFIT.JANSSEN - STUDY IN HOSPITALIZED PATIENTS WITH INFLUENZA A AND PARALLEL PHASE 3 STUDY OF PIMODIVIR IN OUTPATIENTS WITH INFLUENZA A WILL BE HALTED.

Enigma Biomedical Group Signs Agreement To License Novel Neuro Imaging Biomarkers From Janssen

Aug 31 (Reuters) - Johnson & Johnson <JNJ.N>::ENIGMA BIOMEDICAL GROUP SIGNS AGREEMENT TO LICENSE NOVEL NEURO IMAGING BIOMARKERS FROM JANSSEN.ENIGMA BIOMEDICAL GROUP - AGREEMENTS PERMIT EBG TO EVALUATE JANSSEN'S PET LIGANDS.ENIGMA BIOMEDICAL GROUP- IF EVALUATION OF JANSSEN'S PET LIGANDS IS FAVORABLE, GRANT TO CO OF OPTION TO NEGOTIATE EXCLUSIVE LICENSE TO EACH PET LIGAND.

FDA Says Removed Boxed Warning About Risk Of Leg & Foot Amputations For Diabetes Medicine Canagliflozin

Aug 26 (Reuters) - FDA::FDA - REMOVED BOXED WARNING ABOUT RISK OF LEG & FOOT AMPUTATIONS FOR DIABETES MEDICINE CANAGLIFLOZIN (INVOKANA, INVOKAMET, INVOKAMET XR).

Aetion Announces $19 Mln Extension To Its Series B Funding Round

Aug 26 (Reuters) - Johnson & Johnson <JNJ.N>::AETION ADDS STRATEGIC INVESTMENT FROM JOHNSON & JOHNSON INNOVATION - JJDC, INC., EDBI, GREENSPRING ASSOCIATES.AETION - ANNOUNCED A $19 MILLION EXTENSION TO ITS SERIES B FUNDING ROUND.AETION - INVESTMENT BRINGS TOTAL FUNDING TO $94 MILLION SINCE ITS 2015 COMMERCIAL LAUNCH.

Ligand Announces Amgen’S Kyprolis Approved By FDA To Treat Multiple Myeloma

Aug 24 (Reuters) - Ligand Pharmaceuticals Inc <LGND.O>::LIGAND ANNOUNCES AMGEN’S KYPROLIS® APPROVED BY FDA AS COMBINATION REGIMEN WITH DARZALEX® AND DEXAMETHASONE IN ONCE- AND TWICE-WEEKLY DOSING REGIMENS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.LIGAND PHARMACEUTICALS - AMGEN HAS SUBMITTED ADDITIONAL MARKETING APPLICATIONS GLOBALLY FOR KYPROLIS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up